ReNeuron Group says sees data for therapy candidate for disability in H1 2016

24 September 2015

UK-based ReNeuron Group (AIM: RENE) on Thursday said it expects data from its treatment candidate for disability caused by ischemic stroke in the first half of 2016.

The CTX stem cell therapy candidate is currently in the Phase II clinical trial in the UK, the company said in a trading statement. Following the data the company plans to submit an application to start a controlled, pivotal Phase II/III clinical trial in chronically disabled stroke patients.

In addition, ReNeuron expects its CTX cell therapy candidate for critical limb ischemia to move to Phase II development by mid-2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK